Want a memory boost? Eat dark chocolate for better focus and recall
Think twice before passing up that piece of dark chocolate. While it might not be as creamy as milk chocolate, it could work wonders for your memory, especially as the years go by.
Dark chocolate, particularly those rich in cocoa, 70 per cent or higher, is packed with flavonoids, which are antioxidants that have been proven to boost cognitive function. So, that indulgent bite not only satisfies your sweet tooth but could also give your brain a much-needed memory boost. Take your pick. You might just be feeding your mind along with your cravings. How dark chocolate supports memory
Dark chocolate isn't just a treat for your taste buds, it helps your brain, too. As Tamara Alizeh, a clinical dietician based in Dubai, explains, the flavonoids in dark chocolate play a crucial role in boosting blood circulation to the brain. 'When you consume dark chocolate, these powerful compounds help improve the flow of oxygen and essential nutrients to your brain cells,' she says.
This circulation supports cognitive performance, as it allows the brain to function at its best. With more oxygen reaching brain cells, memory and focus can sharpen, mental clarity improves, and overall brain function gets a boost. So, it contributes to the brain staying sharp, focused, and at the top of its game.
A 2009 study published in Neuropsychology, Development, and Cognition found that flavanol-rich cocoa significantly enhanced cognitive performance in elderly participants. The study, titled Flavanol-rich cocoa improves cognitive function of healthy elderly humans by R.W. Scholey, J.M. Owen, and S.W. Pipingas, revealed that participants who consumed cocoa with high levels of flavanols exhibited improvements in tasks involving attention, memory, and processing speed.
These effects were particularly notable after regular consumption over a period, reinforcing the idea that flavonoid-rich foods like dark chocolate can offer long-term cognitive benefits. A tool for keeping the brain sharp
Ever wonder how your brain stays sharp, even as the years go by? That's due to a remarkable ability known as neuroplasticity, your brain's superpower to rewire itself, forming new connections and adapting to fresh experiences. Whether you're learning a new skill, solving complex problems, or just remembering where you left your keys, neuroplasticity is the secret behind it all. And guess what? Dark chocolate boosts this process.
The key players in this chocolate-powered brain boost are flavonoids, particularly epicatechins, which are packed into dark chocolate. These compounds have been shown to spark neuroplasticity.
Stimulating Brain-Derived Neurotrophic Factor (BDNF):
The flavonoids in dark chocolate are thought to boost levels of Brain-Derived Neurotrophic Factor (BDNF), a protein important for the growth and survival of brain cells. As Alizeh and Kara Neal, a London-based consulting physician, explain, 'BDNF helps facilitate the formation of new synapses, the connections between neurons, and supports the brain's ability to adapt and reorganise itself.'
Higher levels of BDNF have been associated with improved learning, memory, and neuroplasticity. Studies suggest that consuming flavonoid-rich cocoa can significantly boost the production of BDNF, especially in areas of the brain involved in memory, like the hippocampus.
A 2009 study published in Neuropsychologia found that cocoa flavonoids can increase BDNF production, which might explain their cognitive benefits.
Promoting the growth of new brain cells
Neuroplasticity doesn't just involve creating new connections—it also includes growing new brain cells, a process called neurogenesis. Research suggests that the flavonoids in dark chocolate can boost neurogenesis, particularly in the hippocampus, which plays a crucial role in learning and memory. The more new neurons your brain creates, the better it can store and recall information.
This means dark chocolate may not only help you retain new information more effectively but could also accelerate your ability to learn new skills or tasks. For example, a 2013 study published in Nature Neuroscience showed that flavonoids promote neurogenesis and synaptic plasticity in rodents, key aspects of memory and learning.
Improved synaptic plasticity
Synaptic plasticity refers to the ability of synapses, the connections between neurons, to strengthen or weaken over time, depending on the frequency and intensity of neural activity. The more effective the synaptic connections are, the better the brain can transmit information. Flavonoids found in dark chocolate can enhance synaptic plasticity, making your brain more efficient at processing information, and so, improving both short-term memory and long-term retention.
A 2018 study titled Dark chocolate consumption reduces stress and inflammation , published in the US-based National Library of Medicine, demonstrated the cognitive qualities of dark chocolate, asserting that it improved mood, memory and cognition.
Another 2018 study on dark chocolate published in the US-based The Faseb Journal, found that memory and learning could be fuelled by chocolate consumption. The flavonoids tend to accumulate in the areas that are responsible for these functions. However, research is still ongoing.
However experts warn: While dark chocolate offers cognitive benefits, it's not a magical solution. It still contains calories and fats, so moderation is key. Since each brand processes it differently, doing some research on your options is always a good idea before indulging.
Nevertheless, the next time you're tempted to skip that piece of dark chocolate, remember—it's not just a sweet treat, but a brain-boosting snack packed with potential.
Sign up for the Daily Briefing
Get the latest news and updates straight to your inbox
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Web Release
4 days ago
- Web Release
Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease
Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study showing that participants treated with Kisunla (donanemab-azbt) demonstrated slowing of decline, a benefit that continued to grow over three years compared to an untreated external cohort from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Participants in the study who started treatment later still saw benefit. However, earlier initiation of Kisunla in study participants significantly reduced the risk of progression to the next stage of the disease compared to those who received Kisunla treatment later. These data were shared as a late breaking 2025 Alzheimer's Association International Conference (AAIC) presentation in Toronto. 'The TRAILBLAZER-ALZ 2 long-term extension reaffirms that Kisunla delivered sustained clinical benefit that continued to increase over three years and a consistent safety profile,' said Mark Mintun, M.D., group vice president, Neuroscience Research & Development, Eli Lilly and Company. 'Participants continued to show meaningful outcomes, reinforcing the long-term value of early intervention.' The TRAILBLAZER-ALZ 2 LTE study was a Phase 3, double-blind extension of the original TRAILBLAZER-ALZ 2 trial, evaluating the efficacy and safety of Kisunla in individuals with early symptomatic Alzheimer's disease. Participants originally treated with Kisunla either continued treatment or were switched to placebo, while those initially on placebo began Kisunla in a blinded manner. An external comparator group from ADNI was used to assess outcomes against a matched, untreated population. Key preliminary results from the TRAILBLAZER-ALZ 2 LTE study include: Kisunla benefit continued to grow over three years for participants treated in the study compared to those in the matched ADNI group. Kisunla reduced cognitive decline by -0.6 at 18 months and then –1.2 at 36 months on the Clinical Dementia Rating Sum of Boxes (CDR-SB) in patients initially treated with Kisunla in the core study compared to the ADNI group. Earlier initiation of Kisunla reduced the risk of progression to the next stage of disease by 27% on the Clinical Dementia Rating-Global Score (CDR-G) compared to a delayed initiation Kisunla group. More than 75% of participants treated with Kisunla reached amyloid clearance within 76 weeks of starting treatment. After up to 2.5 years of observed data in participants who had completed treatment, amyloid plaque reaccumulation remained slow at a rate of approximately 2.4 CL/year, consistent with prior observations and modeling. No new safety signals were observed in the LTE over the three years, further reinforcing the established safety profile for Kisunla. Amyloid-related imaging abnormalities (ARIA) with edema/effusion (ARIA-E) and with hemorrhage/with hemosiderin deposition are side effects within the class of amyloid targeting therapies that do not usually cause any symptoms, but serious and life-threatening symptoms can occur. ARIA can be fatal. Carriers of one or two copies of the apolipoprotein E ?4 (ApoE4) gene may be at higher risk of developing Alzheimer's disease and experiencing ARIA. Patients should discuss any safety concerns with their healthcare providers. Kisunla can also cause certain types of allergic reactions, some of which may be serious and life-threatening, that typically occur during infusion or within 30 minutes post-infusion. Headache is another commonly reported side effect. See the Indication and Safety Summary with Warnings below for additional information. About TRAILBLAZER-ALZ 2 Long-Term Extension (LTE) Study Participants in the TRAILBLAZER-ALZ 2 (core) study who completed the 76-week placebo-controlled period were eligible to continue into the participant- and investigator-blinded LTE period, lasting an additional 78 weeks. The LTE study included multiple treatment arms: Participants (n=550) initially treated with Kisunla in the main study either continued treatment in the LTE or were switched to placebo after meeting pre-defined amyloid clearance thresholds. These participants were followed in the LTE period to assess long-term Kisunla safety and durability of treatment effects. Participants receiving placebo in the main study switched to Kisunla at the start of the LTE period in a blinded manner to evaluate delayed treatment outcomes. These delayed start participants (n= 657) received Kisunla with the same dosing, administration and stopping criteria as the TRAILBLAZER-ALZ 2 trial. In the study, if the amyloid plaque level was <11 Centiloids on a single positron emission tomography (PET) scan or 11 to <25 Centiloids on 2 consecutive PET scans, the patient was eligible to be switched to placebo. For reference, <24.1 Centiloids on an amyloid PET scan is consistent with a negative visual read. About TRAILBLAZER-ALZ 2 Study and the TRAILBLAZER-ALZ Program TRAILBLAZER?ALZ 2 (NCT04437511) is a multicenter, randomized, double-blind, placebo-controlled (PC) Phase 3 trial designed to assess the efficacy and safety of donanemab in participants with early symptomatic Alzheimer's disease. Lilly continues to study donanemab Kisunla in multiple clinical trials, including TRAILBLAZER-ALZ 3, which is evaluating the safety and efficacy of donanemab in patients with preclinical Alzheimer's disease to determine if it reduces risk of progression to symptomatic Alzheimer's disease. TRAILBLAZER-ALZ 5 is a registration trial for early symptomatic Alzheimer's disease currently enrolling in China, Korea, Taiwan, and other geographies. The TRAILBLAZER-ALZ 6 study recently completed the 18-month final study endpoint. Data from the study showed that a modified titration dosing schedule reduced the risk of ARIA-E compared to the TRAILBLAZER-ALZ 2 dosing regimen. These findings supported the FDA approval of an update to the U.S. prescribing information for Kisunla. This data was also presented at AAIC. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram and LinkedIn. P-LLY Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Kisunla (donanemab-azbt) as a treatment for people with early symptomatic Alzheimer's disease, and regulatory approval and other milestones relating to Kisunla and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study findings to date, that Kisunla will receive additional regulatory approvals or that Kisunla will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. References
Khaleej Times
6 days ago
- Khaleej Times
UAE resident nearly dies after headache, loses part of skull in life-saving surgery
For 32-year-old Ananta Sahu, what began as a simple headache quickly turned into the most terrifying experience of his life. Over the course of a week, the pain became unbearable. He developed a high fever, stiffness in his neck, and could barely hold himself steady. Although he sensed something was wrong, he never imagined the situation was life-threatening. 'I had a terrible headache that wouldn't go away,' Ananta said. 'My neck hurt badly, and I had a constant fever. I couldn't even sit or walk properly. The pain kept getting worse, and I was scared I wouldn't survive.' As his condition rapidly worsened, Ananta was rushed to Ras Al Khaimah's Hospital's emergency department. Doctors immediately recognised a dangerous pattern of fever, headache, and neck stiffness — classic signs of a possible brain infection, which are often mistaken for the flu or muscle strain. An MRI scan revealed swelling in the cerebellum, the part of the brain responsible for balance and coordination. A follow-up scan confirmed their fears: Ananta had a brain abscess — a rare but serious infection that causes a build-up of pus in the brain. It not treated quickly, it can lead to stroke, meningitis, or even death. 'Brain abscesses are extremely dangerous and can progress quickly,' said Dr Tinku Jose Kurisinkal, consultant neurosurgeon at RAK Hospital. 'This patient's condition was critical because the infection had advanced rapidly. The challenge is that their symptoms often mimic less severe conditions. Fortunately, our team acted fast and didn't overlook the signs.' The neurosurgery team performed an emergency suboccipital craniectomy, a procedure where a part of the skull is temporarily removed to reach and drain the abscess. The surgery was successful, and Ananta's condition began improving within hours. Brain abscesses are rare, but they can develop when infections from the ear, nose, sinuses, or even teeth spread through the bloodstream to the brain. Because the early symptoms resemble migraines, flu, or neck pain, many patients dismiss them or rely on over-the-counter painkillers — often with dangerous consequences. Dr Tinku warns that if someone has a fever along with persistent headache, vomiting, or neck pain, it should never be taken lightly. 'Quick medical checks, especially scans, can help catch these problems early and save lives.' Dr Raza Siddiqui, executive director, RAK Hospital said the case was a reminder of how powerful timely action can be. 'Many people delay seeking care or treat symptoms at home. But in cases like these, even a small delay could be fatal. This story shows how important it is to act early and trust expert care.' Now fully recovered, the RAK resident is back on his feet and deeply grateful for a second chance at lufe. His message to others is simple but powerful: 'Don't ignore pain. Listen to your body. And when in doubt, go to a doctor, before it's too late.'
Zawya
20-07-2025
- Zawya
Kingdom Health signals launch of second phase with JOD 125mln development agreement
Amman, Jordan – Kingdom Health has announced the launch of its second phase of development, marking a significant milestone as the first phase of core construction concludes. The announcement was made during a ceremony held on Thursday, 10 July, at the St. Regis hotel in Amman, where a JOD 125 million agreement was signed between the Kingdom Health and MID Contracting Company. Under this agreement, the contracting company will undertake architectural finishing, interior fit-out, and the installation of electro-mechanical systems for the project's medical and academic facilities. These efforts pave the way for the trial phase, during which vital systems, equipment and operational infrastructure will begin to be integrated. The signing ceremony was attended by Prof. Feras Hawari, Minister of Health; Dr. Azmi Mahafza, Minister of Education and Minister of Higher Education and Scientific Research; Zaher Al-Qatarneh, Secretary General of the Ministry of Investment and Acting General Manager of the Jordan Investment Fund; and Mohammed bin Hassan Mounis, the Acting Charge d'Affaires of the Embassy of the Kingdom of Saudi Arabia in the Hashemite Kingdom of Jordan. They were joined by senior dignitaries, officials from relevant government entities, local and international partners, and representatives from both parties. Commenting on the agreement, Fadi Al-Said, Chairman at the Kingdom Health, stated, 'We are proud of the progress achieved in the Kingdom Health project. This is not just an investment in health and educational infrastructure, it is a long-term investment in people and society. Through strategic partnerships and a clear vision, we aim to establish an institutional model that strengthens Jordan's position as a regional hub for healthcare and education.' Dr. Mahmoud Sarhan, CEO of the Kingdom Health, added, 'The second phase marks a strategic shift toward institutional and operational empowerment. It is when our vision becomes tangible, offering a cutting-edge experience aligned with global standards in healthcare and medical education. This will be based on a smart infrastructure and an integrated operational system that includes advanced communications, facility management, and modern medical technologies, all supported by our global academic and medical partnerships.' Chairman of the Board at MID Contracting Company, Eng. Ala' Al-Masri, further commented, 'We are honored to collaborate on this landmark project, one of pioneering initiatives in Jordan and the region. Being entrusted with responsibilities to deliver on architectural finishing, interior outfitting, and the installation of electro-mechanical systems that require high precision and engineering integration demonstrates the strong faith in the excellence of our services. We are committed to applying best engineering and operational practices to ensure the facilities meet the highest standards of quality, intelligent operation, and safety, enabling the project to fulfill its institutional vision effectively and sustainably.' The Kingdom Health serves as a transformative model in the healthcare and medical education sectors. It reflects the convergence of Jordan's national vision and high-impact investments supported by the Saudi Jordanian Investment Company, a wholly owned subsidiary of PIF. The project is being implemented through a public-private partnership under a build-operate-transfer (BOT) framework, ensuring sustainable investment and a meaningful social and economic impact. Construction is progressing steadily, with full operations expected by the end of 2027. The project spans a built-up area of over 128,000 square meters. Upon its operational phase, it will include the Kingdom University for Medical Sciences with a capacity of 600 seats and state-of-the-art educational facilities. These will integrate modern medical curricula with artificial intelligence and clinical training to graduate a new generation of doctors, researchers, and leaders in healthcare and medical education. Additionally, the project includes a 330-bed university hospital, 72 outpatient clinics, a specialized children's hospital, and five centers of excellence that will directly address major health challenges in Jordan and the region. The project is distinguished by world-class partnerships, notably with University College London (UCL) Medical School as the academic partner and UCLA Health as the medical partner. Beyond its academic and medical impact, the project is expected to generate more than 5,000 direct and indirect job opportunities, with potential for future expansion. It represents a transformative investment in Jordan's future, serving as a driver of economic growth, a catalyst for scientific research, and a destination for medical tourism, in alignment with His Majesty King Abdullah II's vision of establishing Jordan as a regional center of excellence in medical and health education.
